NTRK1 and lung carcinoma: Crizotinib, an ATP-competitive small-molecule inhibitor of receptor tyrosine kinases C-Met, ALK, and ROS1, has shown significant efficacy in patients with advanced ALK-positive lung cancer (Shaw et al. 2020).